The global market for Dermatomyositis Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Dermatomyositis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dermatomyositis Drug.

The Dermatomyositis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dermatomyositis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Dermatomyositis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Dermatomyositis Drug Market Report

Report Metric	Details
Report Name	Dermatomyositis Drug Market
CAGR	5%
Segment by Type	Abatacept Baricitinib Dalazatide Immune Globulin IMO-8400 Others
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	MedImmune LLC, Neovacs SA, Novartis AG, Octapharma AG, Pfizer Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hope Pharmaceuticals Inc, Idera Pharmaceuticals Inc, KPI Therapeutics Inc, Marathon Pharmaceuticals LLC
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dermatomyositis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dermatomyositis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Dermatomyositis Drug Market report?

Ans: The main players in the Dermatomyositis Drug Market are MedImmune LLC, Neovacs SA, Novartis AG, Octapharma AG, Pfizer Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hope Pharmaceuticals Inc, Idera Pharmaceuticals Inc, KPI Therapeutics Inc, Marathon Pharmaceuticals LLC

What are the Application segmentation covered in the Dermatomyositis Drug Market report?

Ans: The Applications covered in the Dermatomyositis Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Dermatomyositis Drug Market report?

Ans: The Types covered in the Dermatomyositis Drug Market report are Abatacept, Baricitinib, Dalazatide, Immune Globulin, IMO-8400, Others

1 Dermatomyositis Drug Market Overview

1.1 Product Definition

1.2 Dermatomyositis Drug by Type

1.2.1 Global Dermatomyositis Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 Abatacept

1.2.3 Baricitinib

1.2.4 Dalazatide

1.2.5 Immune Globulin

1.2.6 IMO-8400

1.2.7 Others

1.3 Dermatomyositis Drug by Application

1.3.1 Global Dermatomyositis Drug Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Dermatomyositis Drug Market Size Estimates and Forecasts

1.4.1 Global Dermatomyositis Drug Revenue 2020-2031

1.4.2 Global Dermatomyositis Drug Sales 2020-2031

1.4.3 Global Dermatomyositis Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Dermatomyositis Drug Market Competition by Manufacturers

2.1 Global Dermatomyositis Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Dermatomyositis Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Dermatomyositis Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Dermatomyositis Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Dermatomyositis Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Dermatomyositis Drug, Product Type & Application

2.7 Global Key Manufacturers of Dermatomyositis Drug, Date of Enter into This Industry

2.8 Global Dermatomyositis Drug Market Competitive Situation and Trends

2.8.1 Global Dermatomyositis Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Dermatomyositis Drug Players Market Share by Revenue

2.8.3 Global Dermatomyositis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Dermatomyositis Drug Market Scenario by Region

3.1 Global Dermatomyositis Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Dermatomyositis Drug Sales by Region: 2020-2031

3.2.1 Global Dermatomyositis Drug Sales by Region: 2020-2025

3.2.2 Global Dermatomyositis Drug Sales by Region: 2026-2031

3.3 Global Dermatomyositis Drug Revenue by Region: 2020-2031

3.3.1 Global Dermatomyositis Drug Revenue by Region: 2020-2025

3.3.2 Global Dermatomyositis Drug Revenue by Region: 2026-2031

3.4 North America Dermatomyositis Drug Market Facts & Figures by Country

3.4.1 North America Dermatomyositis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Dermatomyositis Drug Sales by Country (2020-2031)

3.4.3 North America Dermatomyositis Drug Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Dermatomyositis Drug Market Facts & Figures by Country

3.5.1 Europe Dermatomyositis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Dermatomyositis Drug Sales by Country (2020-2031)

3.5.3 Europe Dermatomyositis Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Dermatomyositis Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Dermatomyositis Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Dermatomyositis Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Dermatomyositis Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Dermatomyositis Drug Market Facts & Figures by Country

3.7.1 Latin America Dermatomyositis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Dermatomyositis Drug Sales by Country (2020-2031)

3.7.3 Latin America Dermatomyositis Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Dermatomyositis Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Dermatomyositis Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Dermatomyositis Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Dermatomyositis Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Dermatomyositis Drug Sales by Type (2020-2031)

4.1.1 Global Dermatomyositis Drug Sales by Type (2020-2025)

4.1.2 Global Dermatomyositis Drug Sales by Type (2026-2031)

4.1.3 Global Dermatomyositis Drug Sales Market Share by Type (2020-2031)

4.2 Global Dermatomyositis Drug Revenue by Type (2020-2031)

4.2.1 Global Dermatomyositis Drug Revenue by Type (2020-2025)

4.2.2 Global Dermatomyositis Drug Revenue by Type (2026-2031)

4.2.3 Global Dermatomyositis Drug Revenue Market Share by Type (2020-2031)

4.3 Global Dermatomyositis Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Dermatomyositis Drug Sales by Application (2020-2031)

5.1.1 Global Dermatomyositis Drug Sales by Application (2020-2025)

5.1.2 Global Dermatomyositis Drug Sales by Application (2026-2031)

5.1.3 Global Dermatomyositis Drug Sales Market Share by Application (2020-2031)

5.2 Global Dermatomyositis Drug Revenue by Application (2020-2031)

5.2.1 Global Dermatomyositis Drug Revenue by Application (2020-2025)

5.2.2 Global Dermatomyositis Drug Revenue by Application (2026-2031)

5.2.3 Global Dermatomyositis Drug Revenue Market Share by Application (2020-2031)

5.3 Global Dermatomyositis Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 MedImmune LLC

6.1.1 MedImmune LLC Company Information

6.1.2 MedImmune LLC Description and Business Overview

6.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 MedImmune LLC Dermatomyositis Drug Product Portfolio

6.1.5 MedImmune LLC Recent Developments/Updates

6.2 Neovacs SA

6.2.1 Neovacs SA Company Information

6.2.2 Neovacs SA Description and Business Overview

6.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Neovacs SA Dermatomyositis Drug Product Portfolio

6.2.5 Neovacs SA Recent Developments/Updates

6.3 Novartis AG

6.3.1 Novartis AG Company Information

6.3.2 Novartis AG Description and Business Overview

6.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Novartis AG Dermatomyositis Drug Product Portfolio

6.3.5 Novartis AG Recent Developments/Updates

6.4 Octapharma AG

6.4.1 Octapharma AG Company Information

6.4.2 Octapharma AG Description and Business Overview

6.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Octapharma AG Dermatomyositis Drug Product Portfolio

6.4.5 Octapharma AG Recent Developments/Updates

6.5 Pfizer Inc

6.5.1 Pfizer Inc Company Information

6.5.2 Pfizer Inc Description and Business Overview

6.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Pfizer Inc Dermatomyositis Drug Product Portfolio

6.5.5 Pfizer Inc Recent Developments/Updates

6.6 Eli Lilly and Company

6.6.1 Eli Lilly and Company Company Information

6.6.2 Eli Lilly and Company Description and Business Overview

6.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Eli Lilly and Company Dermatomyositis Drug Product Portfolio

6.6.5 Eli Lilly and Company Recent Developments/Updates

6.7 F. Hoffmann-La Roche Ltd

6.7.1 F. Hoffmann-La Roche Ltd Company Information

6.7.2 F. Hoffmann-La Roche Ltd Description and Business Overview

6.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Portfolio

6.7.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

6.8 Hope Pharmaceuticals Inc

6.8.1 Hope Pharmaceuticals Inc Company Information

6.8.2 Hope Pharmaceuticals Inc Description and Business Overview

6.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio

6.8.5 Hope Pharmaceuticals Inc Recent Developments/Updates

6.9 Idera Pharmaceuticals Inc

6.9.1 Idera Pharmaceuticals Inc Company Information

6.9.2 Idera Pharmaceuticals Inc Description and Business Overview

6.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio

6.9.5 Idera Pharmaceuticals Inc Recent Developments/Updates

6.10 KPI Therapeutics Inc

6.10.1 KPI Therapeutics Inc Company Information

6.10.2 KPI Therapeutics Inc Description and Business Overview

6.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.10.4 KPI Therapeutics Inc Dermatomyositis Drug Product Portfolio

6.10.5 KPI Therapeutics Inc Recent Developments/Updates

6.11 Marathon Pharmaceuticals LLC

6.11.1 Marathon Pharmaceuticals LLC Company Information

6.11.2 Marathon Pharmaceuticals LLC Description and Business Overview

6.11.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Portfolio

6.11.5 Marathon Pharmaceuticals LLC Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Dermatomyositis Drug Industry Chain Analysis

7.2 Dermatomyositis Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Dermatomyositis Drug Production Mode & Process Analysis

7.4 Dermatomyositis Drug Sales and Marketing

7.4.1 Dermatomyositis Drug Sales Channels

7.4.2 Dermatomyositis Drug Distributors

7.5 Dermatomyositis Drug Customer Analysis

8 Dermatomyositis Drug Market Dynamics

8.1 Dermatomyositis Drug Industry Trends

8.2 Dermatomyositis Drug Market Drivers

8.3 Dermatomyositis Drug Market Challenges

8.4 Dermatomyositis Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Eli Lilly and Company

F Hoffmann La Roche Ltd

Hope Pharmaceuticals Inc

Idera Pharmaceuticals, Inc.

KPI Therapeutics Inc

Marathon Pharmaceuticals LLC

List of Tables

Table 1. Global Dermatomyositis Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Dermatomyositis Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Dermatomyositis Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Dermatomyositis Drug Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Dermatomyositis Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Dermatomyositis Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Dermatomyositis Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Dermatomyositis Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Dermatomyositis Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Dermatomyositis Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Dermatomyositis Drug, Product Type & Application

Table 12. Global Key Manufacturers of Dermatomyositis Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Dermatomyositis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dermatomyositis Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Dermatomyositis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Dermatomyositis Drug Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Dermatomyositis Drug Sales Market Share by Region (2020-2025)

Table 19. Global Dermatomyositis Drug Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Dermatomyositis Drug Sales Market Share by Region (2026-2031)

Table 21. Global Dermatomyositis Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Dermatomyositis Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Dermatomyositis Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Dermatomyositis Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Dermatomyositis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Dermatomyositis Drug Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Dermatomyositis Drug Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Dermatomyositis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Dermatomyositis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Dermatomyositis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Dermatomyositis Drug Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Dermatomyositis Drug Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Dermatomyositis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Dermatomyositis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Dermatomyositis Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Dermatomyositis Drug Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Dermatomyositis Drug Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Dermatomyositis Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Dermatomyositis Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Dermatomyositis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Dermatomyositis Drug Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Dermatomyositis Drug Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Dermatomyositis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Dermatomyositis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Dermatomyositis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Dermatomyositis Drug Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Dermatomyositis Drug Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Dermatomyositis Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Dermatomyositis Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Dermatomyositis Drug Sales (K Pcs) by Type (2020-2025)

Table 51. Global Dermatomyositis Drug Sales (K Pcs) by Type (2026-2031)

Table 52. Global Dermatomyositis Drug Sales Market Share by Type (2020-2025)

Table 53. Global Dermatomyositis Drug Sales Market Share by Type (2026-2031)

Table 54. Global Dermatomyositis Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Dermatomyositis Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Dermatomyositis Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Dermatomyositis Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Dermatomyositis Drug Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Dermatomyositis Drug Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Dermatomyositis Drug Sales (K Pcs) by Application (2020-2025)

Table 61. Global Dermatomyositis Drug Sales (K Pcs) by Application (2026-2031)

Table 62. Global Dermatomyositis Drug Sales Market Share by Application (2020-2025)

Table 63. Global Dermatomyositis Drug Sales Market Share by Application (2026-2031)

Table 64. Global Dermatomyositis Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Dermatomyositis Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Dermatomyositis Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Dermatomyositis Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Dermatomyositis Drug Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Dermatomyositis Drug Price (USD/Pcs) by Application (2026-2031)

Table 70. MedImmune LLC Company Information

Table 71. MedImmune LLC Description and Business Overview

Table 72. MedImmune LLC Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. MedImmune LLC Dermatomyositis Drug Product

Table 74. MedImmune LLC Recent Developments/Updates

Table 75. Neovacs SA Company Information

Table 76. Neovacs SA Description and Business Overview

Table 77. Neovacs SA Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Neovacs SA Dermatomyositis Drug Product

Table 79. Neovacs SA Recent Developments/Updates

Table 80. Novartis AG Company Information

Table 81. Novartis AG Description and Business Overview

Table 82. Novartis AG Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Novartis AG Dermatomyositis Drug Product

Table 84. Novartis AG Recent Developments/Updates

Table 85. Octapharma AG Company Information

Table 86. Octapharma AG Description and Business Overview

Table 87. Octapharma AG Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Octapharma AG Dermatomyositis Drug Product

Table 89. Octapharma AG Recent Developments/Updates

Table 90. Pfizer Inc Company Information

Table 91. Pfizer Inc Description and Business Overview

Table 92. Pfizer Inc Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Pfizer Inc Dermatomyositis Drug Product

Table 94. Pfizer Inc Recent Developments/Updates

Table 95. Eli Lilly and Company Company Information

Table 96. Eli Lilly and Company Description and Business Overview

Table 97. Eli Lilly and Company Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. Eli Lilly and Company Dermatomyositis Drug Product

Table 99. Eli Lilly and Company Recent Developments/Updates

Table 100. F. Hoffmann-La Roche Ltd Company Information

Table 101. F. Hoffmann-La Roche Ltd Description and Business Overview

Table 102. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product

Table 104. F. Hoffmann-La Roche Ltd Recent Developments/Updates

Table 105. Hope Pharmaceuticals Inc Company Information

Table 106. Hope Pharmaceuticals Inc Description and Business Overview

Table 107. Hope Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. Hope Pharmaceuticals Inc Dermatomyositis Drug Product

Table 109. Hope Pharmaceuticals Inc Recent Developments/Updates

Table 110. Idera Pharmaceuticals Inc Company Information

Table 111. Idera Pharmaceuticals Inc Description and Business Overview

Table 112. Idera Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. Idera Pharmaceuticals Inc Dermatomyositis Drug Product

Table 114. Idera Pharmaceuticals Inc Recent Developments/Updates

Table 115. KPI Therapeutics Inc Company Information

Table 116. KPI Therapeutics Inc Description and Business Overview

Table 117. KPI Therapeutics Inc Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 118. KPI Therapeutics Inc Dermatomyositis Drug Product

Table 119. KPI Therapeutics Inc Recent Developments/Updates

Table 120. Marathon Pharmaceuticals LLC Company Information

Table 121. Marathon Pharmaceuticals LLC Description and Business Overview

Table 122. Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 123. Marathon Pharmaceuticals LLC Dermatomyositis Drug Product

Table 124. Marathon Pharmaceuticals LLC Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Dermatomyositis Drug Distributors List

Table 128. Dermatomyositis Drug Customers List

Table 129. Dermatomyositis Drug Market Trends

Table 130. Dermatomyositis Drug Market Drivers

Table 131. Dermatomyositis Drug Market Challenges

Table 132. Dermatomyositis Drug Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Dermatomyositis Drug

Figure 2. Global Dermatomyositis Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Dermatomyositis Drug Market Share by Type: 2024 & 2031

Figure 4. Abatacept Product Picture

Figure 5. Baricitinib Product Picture

Figure 6. Dalazatide Product Picture

Figure 7. Immune Globulin Product Picture

Figure 8. IMO-8400 Product Picture

Figure 9. Others Product Picture

Figure 10. Global Dermatomyositis Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 11. Global Dermatomyositis Drug Market Share by Application: 2024 & 2031

Figure 12. Hospital

Figure 13. Clinic

Figure 14. Others

Figure 15. Global Dermatomyositis Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Dermatomyositis Drug Market Size (2020-2031) & (US$ Million)

Figure 17. Global Dermatomyositis Drug Sales (2020-2031) & (K Pcs)

Figure 18. Global Dermatomyositis Drug Average Price (USD/Pcs) & (2020-2031)

Figure 19. Dermatomyositis Drug Report Years Considered

Figure 20. Dermatomyositis Drug Sales Share by Manufacturers in 2024

Figure 21. Global Dermatomyositis Drug Revenue Share by Manufacturers in 2024

Figure 22. Global 5 and 10 Largest Dermatomyositis Drug Players: Market Share by Revenue in Dermatomyositis Drug in 2024

Figure 23. Dermatomyositis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 24. Global Dermatomyositis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 25. North America Dermatomyositis Drug Sales Market Share by Country (2020-2031)

Figure 26. North America Dermatomyositis Drug Revenue Market Share by Country (2020-2031)

Figure 27. U.S. Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Canada Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Europe Dermatomyositis Drug Sales Market Share by Country (2020-2031)

Figure 30. Europe Dermatomyositis Drug Revenue Market Share by Country (2020-2031)

Figure 31. Germany Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. France Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. U.K. Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Italy Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Russia Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Asia Pacific Dermatomyositis Drug Sales Market Share by Region (2020-2031)

Figure 37. Asia Pacific Dermatomyositis Drug Revenue Market Share by Region (2020-2031)

Figure 38. China Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Japan Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. South Korea Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. India Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Australia Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Taiwan Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Indonesia Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Thailand Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Malaysia Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Philippines Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Latin America Dermatomyositis Drug Sales Market Share by Country (2020-2031)

Figure 49. Latin America Dermatomyositis Drug Revenue Market Share by Country (2020-2031)

Figure 50. Mexico Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Brazil Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Argentina Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Middle East and Africa Dermatomyositis Drug Sales Market Share by Country (2020-2031)

Figure 54. Middle East and Africa Dermatomyositis Drug Revenue Market Share by Country (2020-2031)

Figure 55. Turkey Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Saudi Arabia Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. UAE Dermatomyositis Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Global Sales Market Share of Dermatomyositis Drug by Type (2020-2031)

Figure 59. Global Revenue Market Share of Dermatomyositis Drug by Type (2020-2031)

Figure 60. Global Dermatomyositis Drug Price (USD/Pcs) by Type (2020-2031)

Figure 61. Global Sales Market Share of Dermatomyositis Drug by Application (2020-2031)

Figure 62. Global Revenue Market Share of Dermatomyositis Drug by Application (2020-2031)

Figure 63. Global Dermatomyositis Drug Price (USD/Pcs) by Application (2020-2031)

Figure 64. Dermatomyositis Drug Value Chain

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6Q20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-35Z19949

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26E19785

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions